Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Inotiv Inc (NOTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: NOTV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.62% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 72.83M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 3 | Beta 4.1 | 52 Weeks Range 1.15 - 6.48 | Updated Date 07/9/2025 |
52 Weeks Range 1.15 - 6.48 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -18.21% | Operating Margin (TTM) -7.62% |
Management Effectiveness
Return on Assets (TTM) -2.31% | Return on Equity (TTM) -47.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 505123313 | Price to Sales(TTM) 0.15 |
Enterprise Value 505123313 | Price to Sales(TTM) 0.15 | ||
Enterprise Value to Revenue 1.05 | Enterprise Value to EBITDA 89.35 | Shares Outstanding 34353000 | Shares Floating 31206932 |
Shares Outstanding 34353000 | Shares Floating 31206932 | ||
Percent Insiders 11.32 | Percent Institutions 23.8 |
Upturn AI SWOT
Inotiv Inc
Company Overview
History and Background
Inotiv, Inc. was founded in 1974 as Bioanalytical Systems, Inc. (BASi). It has grown through acquisitions and organic expansion, transforming from a provider of bioanalytical services to a broader contract research organization (CRO) serving the drug discovery and development market. Significant milestones include strategic acquisitions of companies specializing in toxicology, pharmacology, and related services.
Core Business Areas
- Discovery and Safety Assessment: Provides comprehensive preclinical services, including toxicology, pathology, pharmacology, and bioanalysis, to help pharmaceutical, biotechnology, and government entities discover and develop new drugs and therapies. This includes conducting safety and efficacy studies.
- Research Models and Services: Offers a variety of research models, including genetically modified animals and related services, supporting preclinical research and development. This includes the sourcing, breeding, and characterization of research models.
- Analytical Services: Provides services, including bioanalysis, drug metabolism and pharmacokinetics (DMPK), and formulation development, which supports drug development and regulatory compliance.
Leadership and Structure
The leadership team consists of the CEO, CFO, COO, and various VPs responsible for different business units. The organizational structure is hierarchical, with reporting lines from business unit leaders to executive management. The company is governed by a Board of Directors.
Top Products and Market Share
Key Offerings
- Toxicology Services: Offers a range of toxicology studies to assess the safety of drug candidates. The market is highly competitive with companies like Charles River Laboratories (CRL), WuXi AppTec (WX), and Labcorp (LH). Market share data is not publicly disclosable but estimated to be low single digits given the fragmented market.
- Research Models: Provides various research models, including genetically modified animals, for preclinical research. Competitors include Charles River Laboratories (CRL), Envigo (private), and Taconic Biosciences (private). Market share is in the low single digits.
- Bioanalytical Services: Offers a range of analytical testing services to assess the safety of drug candidates. The market is highly competitive with companies like Charles River Laboratories (CRL), WuXi AppTec (WX), and Labcorp (LH). Market share data is not publicly disclosable but estimated to be low single digits given the fragmented market.
Market Dynamics
Industry Overview
The contract research organization (CRO) industry is experiencing growth driven by increasing R&D spending in the pharmaceutical and biotechnology sectors, rising demand for outsourcing, and increasing complexity of drug development. This includes services from discovery to phase IV clinical trials and post-market support.
Positioning
Inotiv is positioned as a mid-sized CRO specializing in preclinical research and development services. Its competitive advantage lies in its integrated service offerings and expertise in specialized areas such as toxicology and research models.
Total Addressable Market (TAM)
The total addressable market for preclinical CRO services is estimated to be in the billions of dollars. Inotiv is positioned to capture a portion of this market through its specialized service offerings.
Upturn SWOT Analysis
Strengths
- Comprehensive preclinical service offerings
- Expertise in toxicology and pharmacology
- Established relationships with pharmaceutical and biotechnology clients
- Strategic acquisitions to expand capabilities
- Offers diverse Research Models
Weaknesses
- High debt level
- Relatively small scale compared to larger CROs
- Integration challenges from acquisitions
- Dependence on key clients and contracts
- Low profit margins
Opportunities
- Growing demand for preclinical CRO services
- Expansion into new geographic markets
- Increased outsourcing by pharmaceutical companies
- Development of new service offerings
- Market Consolidation by Acquisition
Threats
- Intense competition from larger CROs
- Economic downturn impacting R&D spending
- Regulatory changes in drug development
- Loss of key personnel
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- CRL
- LH
- WX
Competitive Landscape
Inotiv Inc faces intense competition from larger CROs such as Charles River Laboratories, Labcorp, and WuXi AppTec. Its advantages include specialized service offerings and established relationships with clients. Its disadvantages include smaller scale, high debt, and integration challenges.
Major Acquisitions
Envigo RMS Holding Corp
- Year: 2021
- Acquisition Price (USD millions): 545.5
- Strategic Rationale: Expanded research models and services capabilities and market presence.
Bolder BioPATH, Inc
- Year: 2023
- Acquisition Price (USD millions): 11.2
- Strategic Rationale: Expanded research models and services capabilities and market presence.
Growth Trajectory and Initiatives
Historical Growth: Inotiv Inc.'s historical growth has been driven by acquisitions and organic expansion. Revenue growth has been inconsistent, with periods of rapid growth followed by periods of slower growth or decline.
Future Projections: Future growth projections are based on analyst estimates, which vary depending on market conditions and the company's ability to execute its strategic plan. The company is expected to benefit from increased R&D spending and outsourcing trends.
Recent Initiatives: Recent strategic initiatives include acquisitions of companies specializing in toxicology and pharmacology, expansion of service offerings, and investments in new technologies. The company has also focused on integrating its acquired businesses and improving operational efficiency.
Summary
Inotiv, Inc. is a mid-sized CRO with specialized preclinical service offerings that is struggling to compete with larger players. It has grown through acquisition, expanding capabilities in toxicology, research models, and analytical services. The company faces challenges managing debt, integrating acquired businesses, and maintaining profitability. Inotiv needs to focus on improving operational efficiency and organic growth to improve their standing in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is subject to change. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inotiv Inc
Exchange NASDAQ | Headquaters West Lafayette, IN, United States | ||
IPO Launch date 1997-11-25 | President, CEO & Director Mr. Robert W. Leasure Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1977 | Website https://www.inotiv.com |
Full time employees 1977 | Website https://www.inotiv.com | ||
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.